Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$108.11 USD
-0.90 (-0.83%)
Updated Jul 22, 2024 11:08 AM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
JAZZ 108.11 -0.90(-0.83%)
Will JAZZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAZZ
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Other News for JAZZ
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
Buy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic Revaluation
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer